The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
<strong>Background:</strong> Extended-release niacin with laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events in HPS2-THRIVE but its net effects on health and healthcare costs are unknown. <strong>Methods an...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
American Heart Association
2016
|